Isepamicin versus amikacin for the treatment of acute pyelonephritis in children
In this study we compared the efficacy and safety of isepamicin versus amikacin at a dose of 7.5 mg/kg i.v. q12h for 10–14 days in children with pyelonephritis. Sixteen children were enrolled in the study; ten received isepamicin and six amikacin. Urine cultures grew Escherichia coli in all patients...
Gespeichert in:
| Veröffentlicht in: | International journal of antimicrobial agents 2000-02, Vol.14 (1), p.51-55 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 55 |
|---|---|
| container_issue | 1 |
| container_start_page | 51 |
| container_title | International journal of antimicrobial agents |
| container_volume | 14 |
| creator | Kafetzis, D.A Maltezou, H.C Mavrikou, M Siafas, C Paraskakis, I Delis, D Bartsokas, C |
| description | In this study we compared the efficacy and safety of isepamicin versus amikacin at a dose of 7.5 mg/kg i.v. q12h for 10–14 days in children with pyelonephritis. Sixteen children were enrolled in the study; ten received isepamicin and six amikacin. Urine cultures grew
Escherichia coli in all patients. All patients were treated successfully with either isepamicin or amikacin. Clinical and bacteriological response rates were 100% for both groups. No adverse events occurred. Peak serum levels ranged from 9.05 to 30.70 mg/l (median: 16.165) and from 12.20 to 25.90 mg/l (median: 19.05) for isepamicin and amikacin, respectively. Trough serum levels ranged from 0.11 to 3.20 mg/l (median: 0.75) and from 0.1 to 2.1 mg/l (median: 0.655), respectively. Isepamicin was shown to be as effective and safe as amikacin in the treatment of children with pyelonephritis and might prove an advantageous alternative in areas with high incidence of resistance to other aminoglycosides. |
| doi_str_mv | 10.1016/S0924-8579(99)00138-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70977669</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0924857999001387</els_id><sourcerecordid>70977669</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-7f1576123b224ca84939ef473eeb447106e1db93b108c22438d748336b508c053</originalsourceid><addsrcrecordid>eNqF0E1LHDEYwPEgFXe79iNY5lCkPYzNM0kmk5OItHVBUKg9h0zmGTZ13kwywn77Zt3FevMUnvDLC39CzoBeAIXy-2-qCp5XQqqvSn2jFFiVyyOyhEoWuVTAPpDlK1mQjyH8TUgwLk7IAqgEKSgsyf064GR6Z92QPaMPc8jS9Gh2czv6LG4wix5N7HGI2dhmxs4Rs2mL3TjgtPEuupAlbDeuazwOp-S4NV3AT4d1Rf78_PFwfZPf3v1aX1_d5pYXEHPZgpAlFKwuCm5NxRVT2HLJEGvOJdASoakVq4FWNhFWNZJXjJW1SBtUsBU53987-fFpxhB174LFrjMDjnPQkiopy1K9C3chhCogQbGH1o8heGz15F1v_FYD1bvm-qW53gXVSumX5lqmc58PD8x1j82bU_vICXw5ABOs6VpvBuvCf1eoEkSV2OWeYcr27NDrYB0OFhvn0UbdjO6dn_wDMiOcuw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17505921</pqid></control><display><type>article</type><title>Isepamicin versus amikacin for the treatment of acute pyelonephritis in children</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Kafetzis, D.A ; Maltezou, H.C ; Mavrikou, M ; Siafas, C ; Paraskakis, I ; Delis, D ; Bartsokas, C</creator><creatorcontrib>Kafetzis, D.A ; Maltezou, H.C ; Mavrikou, M ; Siafas, C ; Paraskakis, I ; Delis, D ; Bartsokas, C</creatorcontrib><description>In this study we compared the efficacy and safety of isepamicin versus amikacin at a dose of 7.5 mg/kg i.v. q12h for 10–14 days in children with pyelonephritis. Sixteen children were enrolled in the study; ten received isepamicin and six amikacin. Urine cultures grew
Escherichia coli in all patients. All patients were treated successfully with either isepamicin or amikacin. Clinical and bacteriological response rates were 100% for both groups. No adverse events occurred. Peak serum levels ranged from 9.05 to 30.70 mg/l (median: 16.165) and from 12.20 to 25.90 mg/l (median: 19.05) for isepamicin and amikacin, respectively. Trough serum levels ranged from 0.11 to 3.20 mg/l (median: 0.75) and from 0.1 to 2.1 mg/l (median: 0.655), respectively. Isepamicin was shown to be as effective and safe as amikacin in the treatment of children with pyelonephritis and might prove an advantageous alternative in areas with high incidence of resistance to other aminoglycosides.</description><identifier>ISSN: 0924-8579</identifier><identifier>EISSN: 1872-7913</identifier><identifier>DOI: 10.1016/S0924-8579(99)00138-7</identifier><identifier>PMID: 10717501</identifier><language>eng</language><publisher>London: Elsevier B.V</publisher><subject>Amikacin - pharmacokinetics ; Amikacin - therapeutic use ; Anti-Bacterial Agents - pharmacokinetics ; Anti-Bacterial Agents - therapeutic use ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Biological and medical sciences ; Child ; Child, Preschool ; Children ; Escherichia coli ; Escherichia coli - isolation & purification ; Escherichia coli Infections - drug therapy ; Escherichia coli Infections - microbiology ; Female ; Gentamicins - pharmacokinetics ; Gentamicins - therapeutic use ; Humans ; Infant ; Infant, Newborn ; Isepamicin ; Male ; Medical sciences ; Pharmacology. Drug treatments ; Pyelonephritis ; Pyelonephritis - drug therapy ; Pyelonephritis - microbiology ; Treatment Outcome ; Urine - microbiology</subject><ispartof>International journal of antimicrobial agents, 2000-02, Vol.14 (1), p.51-55</ispartof><rights>2000 Elsevier Science B.V.</rights><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-7f1576123b224ca84939ef473eeb447106e1db93b108c22438d748336b508c053</citedby><cites>FETCH-LOGICAL-c421t-7f1576123b224ca84939ef473eeb447106e1db93b108c22438d748336b508c053</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0924857999001387$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1296158$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10717501$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kafetzis, D.A</creatorcontrib><creatorcontrib>Maltezou, H.C</creatorcontrib><creatorcontrib>Mavrikou, M</creatorcontrib><creatorcontrib>Siafas, C</creatorcontrib><creatorcontrib>Paraskakis, I</creatorcontrib><creatorcontrib>Delis, D</creatorcontrib><creatorcontrib>Bartsokas, C</creatorcontrib><title>Isepamicin versus amikacin for the treatment of acute pyelonephritis in children</title><title>International journal of antimicrobial agents</title><addtitle>Int J Antimicrob Agents</addtitle><description>In this study we compared the efficacy and safety of isepamicin versus amikacin at a dose of 7.5 mg/kg i.v. q12h for 10–14 days in children with pyelonephritis. Sixteen children were enrolled in the study; ten received isepamicin and six amikacin. Urine cultures grew
Escherichia coli in all patients. All patients were treated successfully with either isepamicin or amikacin. Clinical and bacteriological response rates were 100% for both groups. No adverse events occurred. Peak serum levels ranged from 9.05 to 30.70 mg/l (median: 16.165) and from 12.20 to 25.90 mg/l (median: 19.05) for isepamicin and amikacin, respectively. Trough serum levels ranged from 0.11 to 3.20 mg/l (median: 0.75) and from 0.1 to 2.1 mg/l (median: 0.655), respectively. Isepamicin was shown to be as effective and safe as amikacin in the treatment of children with pyelonephritis and might prove an advantageous alternative in areas with high incidence of resistance to other aminoglycosides.</description><subject>Amikacin - pharmacokinetics</subject><subject>Amikacin - therapeutic use</subject><subject>Anti-Bacterial Agents - pharmacokinetics</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Escherichia coli</subject><subject>Escherichia coli - isolation & purification</subject><subject>Escherichia coli Infections - drug therapy</subject><subject>Escherichia coli Infections - microbiology</subject><subject>Female</subject><subject>Gentamicins - pharmacokinetics</subject><subject>Gentamicins - therapeutic use</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Isepamicin</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Pyelonephritis</subject><subject>Pyelonephritis - drug therapy</subject><subject>Pyelonephritis - microbiology</subject><subject>Treatment Outcome</subject><subject>Urine - microbiology</subject><issn>0924-8579</issn><issn>1872-7913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0E1LHDEYwPEgFXe79iNY5lCkPYzNM0kmk5OItHVBUKg9h0zmGTZ13kwywn77Zt3FevMUnvDLC39CzoBeAIXy-2-qCp5XQqqvSn2jFFiVyyOyhEoWuVTAPpDlK1mQjyH8TUgwLk7IAqgEKSgsyf064GR6Z92QPaMPc8jS9Gh2czv6LG4wix5N7HGI2dhmxs4Rs2mL3TjgtPEuupAlbDeuazwOp-S4NV3AT4d1Rf78_PFwfZPf3v1aX1_d5pYXEHPZgpAlFKwuCm5NxRVT2HLJEGvOJdASoakVq4FWNhFWNZJXjJW1SBtUsBU53987-fFpxhB174LFrjMDjnPQkiopy1K9C3chhCogQbGH1o8heGz15F1v_FYD1bvm-qW53gXVSumX5lqmc58PD8x1j82bU_vICXw5ABOs6VpvBuvCf1eoEkSV2OWeYcr27NDrYB0OFhvn0UbdjO6dn_wDMiOcuw</recordid><startdate>200002</startdate><enddate>200002</enddate><creator>Kafetzis, D.A</creator><creator>Maltezou, H.C</creator><creator>Mavrikou, M</creator><creator>Siafas, C</creator><creator>Paraskakis, I</creator><creator>Delis, D</creator><creator>Bartsokas, C</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>200002</creationdate><title>Isepamicin versus amikacin for the treatment of acute pyelonephritis in children</title><author>Kafetzis, D.A ; Maltezou, H.C ; Mavrikou, M ; Siafas, C ; Paraskakis, I ; Delis, D ; Bartsokas, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-7f1576123b224ca84939ef473eeb447106e1db93b108c22438d748336b508c053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Amikacin - pharmacokinetics</topic><topic>Amikacin - therapeutic use</topic><topic>Anti-Bacterial Agents - pharmacokinetics</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Escherichia coli</topic><topic>Escherichia coli - isolation & purification</topic><topic>Escherichia coli Infections - drug therapy</topic><topic>Escherichia coli Infections - microbiology</topic><topic>Female</topic><topic>Gentamicins - pharmacokinetics</topic><topic>Gentamicins - therapeutic use</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Isepamicin</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Pyelonephritis</topic><topic>Pyelonephritis - drug therapy</topic><topic>Pyelonephritis - microbiology</topic><topic>Treatment Outcome</topic><topic>Urine - microbiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kafetzis, D.A</creatorcontrib><creatorcontrib>Maltezou, H.C</creatorcontrib><creatorcontrib>Mavrikou, M</creatorcontrib><creatorcontrib>Siafas, C</creatorcontrib><creatorcontrib>Paraskakis, I</creatorcontrib><creatorcontrib>Delis, D</creatorcontrib><creatorcontrib>Bartsokas, C</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of antimicrobial agents</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kafetzis, D.A</au><au>Maltezou, H.C</au><au>Mavrikou, M</au><au>Siafas, C</au><au>Paraskakis, I</au><au>Delis, D</au><au>Bartsokas, C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Isepamicin versus amikacin for the treatment of acute pyelonephritis in children</atitle><jtitle>International journal of antimicrobial agents</jtitle><addtitle>Int J Antimicrob Agents</addtitle><date>2000-02</date><risdate>2000</risdate><volume>14</volume><issue>1</issue><spage>51</spage><epage>55</epage><pages>51-55</pages><issn>0924-8579</issn><eissn>1872-7913</eissn><abstract>In this study we compared the efficacy and safety of isepamicin versus amikacin at a dose of 7.5 mg/kg i.v. q12h for 10–14 days in children with pyelonephritis. Sixteen children were enrolled in the study; ten received isepamicin and six amikacin. Urine cultures grew
Escherichia coli in all patients. All patients were treated successfully with either isepamicin or amikacin. Clinical and bacteriological response rates were 100% for both groups. No adverse events occurred. Peak serum levels ranged from 9.05 to 30.70 mg/l (median: 16.165) and from 12.20 to 25.90 mg/l (median: 19.05) for isepamicin and amikacin, respectively. Trough serum levels ranged from 0.11 to 3.20 mg/l (median: 0.75) and from 0.1 to 2.1 mg/l (median: 0.655), respectively. Isepamicin was shown to be as effective and safe as amikacin in the treatment of children with pyelonephritis and might prove an advantageous alternative in areas with high incidence of resistance to other aminoglycosides.</abstract><cop>London</cop><cop>Amsterdam</cop><cop>New York, NY</cop><pub>Elsevier B.V</pub><pmid>10717501</pmid><doi>10.1016/S0924-8579(99)00138-7</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0924-8579 |
| ispartof | International journal of antimicrobial agents, 2000-02, Vol.14 (1), p.51-55 |
| issn | 0924-8579 1872-7913 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70977669 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Amikacin - pharmacokinetics Amikacin - therapeutic use Anti-Bacterial Agents - pharmacokinetics Anti-Bacterial Agents - therapeutic use Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Biological and medical sciences Child Child, Preschool Children Escherichia coli Escherichia coli - isolation & purification Escherichia coli Infections - drug therapy Escherichia coli Infections - microbiology Female Gentamicins - pharmacokinetics Gentamicins - therapeutic use Humans Infant Infant, Newborn Isepamicin Male Medical sciences Pharmacology. Drug treatments Pyelonephritis Pyelonephritis - drug therapy Pyelonephritis - microbiology Treatment Outcome Urine - microbiology |
| title | Isepamicin versus amikacin for the treatment of acute pyelonephritis in children |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T02%3A22%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Isepamicin%20versus%20amikacin%20for%20the%20treatment%20of%20acute%20pyelonephritis%20in%20children&rft.jtitle=International%20journal%20of%20antimicrobial%20agents&rft.au=Kafetzis,%20D.A&rft.date=2000-02&rft.volume=14&rft.issue=1&rft.spage=51&rft.epage=55&rft.pages=51-55&rft.issn=0924-8579&rft.eissn=1872-7913&rft_id=info:doi/10.1016/S0924-8579(99)00138-7&rft_dat=%3Cproquest_cross%3E70977669%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17505921&rft_id=info:pmid/10717501&rft_els_id=S0924857999001387&rfr_iscdi=true |